Scleroderma Market Outlook - Estimated Market Size And Growth Rate 2023-2032

The Business Research Company's global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company's Scleroderma Global Market Report 2023 identifies greater prevalence of scleroderma as the major driver for the Scleroderma market's growth in the forecast period. Scleroderma is a chronic autoimmune disease characterized by the abnormal growth of collagen, a protein that forms the structure of skin and other tissues. An unregulated immune response, possibly triggered by various environmental factors, leads to the development of this condition. As the number of cases rises, the importance of improved diagnosis and treatment becomes evident. Scleroderma therapeutics are crucial to managing illness and alleviating symptoms by regulating the immune response and mitigating exposure to environmental risk factors.

the global scleroderma market is expected to grow from $2 billion in 2022 to $2.15 billion in 2023 at a compound annual growth rate (CAGR) of 7.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic. The war between these two countries has led to economic sanctions on multiple countries, surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and resulted in increased interest rates affecting many markets across the globe. The scleroderma market is expected to reach $2.78 billion in 2027 at a CAGR of 6.6%.
Download Free Sample Of Scleroderma Market Report -
https://www.thebusinessresearchcompany.com/sample_request?id=12615&type=smp

Major competitors in the Scleroderma market are Pfizer Inc., Johnson And Johnson Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc.

A key trend in the Scleroderma market includes developing novel treatments. Major companies in the scleroderma market are developing novel drugs to manage the symptoms and sustain their position in the market. For instance, in April 2022, Tyr Pharma Inc., a US-based biotherapeutics manufacturer, received regulatory approval for its novel systemic sclerosis-related interstitial lung disease drug efzofitimod from the US Food and Drug Administration, a US-based health regulatory agency. The new drug is a First-in-class immunomodulator to downregulate and control the immune response by modulating the neuropilin-2 (NRP2) receptor to reduce symptoms of scleroderma. Additionally, Efzofitimod also targets the same immune cells responsible for the pathology of SSc-ILD (interstitial lung disease associated with systemic sclerosis) and pulmonary sarcoidosis, leading to reduced pro-inflammatory markers in a clinical study with patients suffering from pulmonary sarcoidosis.

Read More On The Global Scleroderma Market Report Here:
https://www.thebusinessresearchcompany.com/report/scleroderma-global-market-report

The Scleroderma market is segmented -
• By Treatment: Medication, Surgery, Other Treatments
• By Indication: Systemic Scleroderma, Localized Scleroderma
• By End User: Hospital, Pharmaceutical Stores, Other End Users
• By Geography: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. North America was the largest region in the Scleroderma market.

The Business Research Company's "Global Scleroderma Market Report 2023" provides a thorough understanding of the market across 60 geographies. The report covers market size, growth rate, segments, drivers and trends in every region and country. In addition, the report offers insights on historical and forecast growth, helping players analyze and strategize better.

Explore Buying Options For The Scleroderma Market Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12615

The Table Of Content For The Scleroderma Market Include:

1. Scleroderma Market Executive Summary
2. Scleroderma Market Segments
3. Scleroderma Market Size And Scleroderma Market Growth Rate
4. Key Scleroderma Market Trends
5. Major Scleroderma Market Drivers
……
25. Key Mergers And Acquisitions In The Scleroderma Market
26. Top Scleroderma Companies
27. Scleroderma Market Opportunities And Strategies
28. Scleroderma Market, Conclusions And Recommendations
29. Appendix

Contact us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Latest Trending Press Releases: https://www.thebusinessresearchcompany.com/press-release.aspx

Want To Know More About The Business Research Company?
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialise in various industries including manufacturing, healthcare, financial services, chemicals, and technology.

Global Market Model - World's Most Comprehensive Database
The Business Research Company's flagship product, Global Market Model (www.thebusinessresearchcompany.com/global-market-model) is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.

This release was published on openPR.